Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

MLN0128, a Potential Target Therapy for Myeloid Proliferation Neoplasia (MPN) with a Benefit of Prolonging Survival

Rachana Patil, Nitza Vara, Peter D. Emanuel, Alice Bertaina, Y. Lucy Liu

Blood (2021) 138 (Supplement 1): 1464.

https://doi.org/10.1182/blood-2021-151976

Published: 2021

Journal Articles

Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy

Y. Lucy Liu, Yan Yan, Cody Webster, Lijian Shao, Shelly Y. Lensing, Hongyu Ni, Wei Feng, Natalia Colorado, Rupak Pathak, Zhifu Xiang, Martin Hauer-Jensen, Shaoguang Li, Daohong Zhou, Peter D. Emanuel

Blood (2016) 127 (15): 1912–1922.

https://doi.org/10.1182/blood-2015-05-646216

Published: 2016

Includes: Supplemental data

Journal Articles

Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia

Elliot Stieglitz, Camille B. Troup, Laura C. Gelston, John Haliburton, Eric D. Chow, Kristie B. Yu, Jon Akutagawa, Amaro N. Taylor-Weiner, Y. Lucy Liu, Yong-Dong Wang, Kyle Beckman, Peter D. Emanuel, Benjamin S. Braun, Adam Abate, Robert B. Gerbing, Todd A. Alonzo, Mignon L. Loh

Blood (2015) 125 (3): 516–524.

https://doi.org/10.1182/blood-2014-09-601690

Published: 2015

Includes: Supplemental data

Journal Articles

Opposite Effects of M1 and M2 Macrophages on Hematopoietic Stem Cell Self-Renewal and Ex Vivo Expansion

Yi Luo, MD PhD, Lijian Shao, MD PhD, Jianhui Chang, MS, Wei Feng, MD, Chengcheng Li, PhDcandidate, Y. Lucy Liu, MD PhD, Michele Cottler-Fox, MD, Peter D Emanuel, MD, Peter Murray, PhD, Daohong Zhou, MD

Blood (2014) 124 (21): 2909.

https://doi.org/10.1182/blood.V124.21.2909.2909

Published: 2014

Journal Articles

Timing of the Loss of Pten Is Critical in Determining the Disease Phenotype in Mice- a Mouse Model for Pediatric Mixed MDS/MPN

Y. Lucy Liu, MD PhD, Yan Yan, MD, Cody Webster, BS, Lijian Shao, MD PhD, Shelly Y. Lensing, MS, Hongyu Ni, MD PhD, Wei Feng, MD, Daohong Zhou, MD, Zhifu Xiang, MD, Natalia Colorado, MD, Delli Robinson, Shaoguang Li, MD PhD, Peter D Emanuel, MD

Blood (2014) 124 (21): 3585.

https://doi.org/10.1182/blood.V124.21.3585.3585

Published: 2014

Journal Articles

Subclonal Mutations in SETBP1 Predict Relapse in Juvenile Myelomonocytic Leukemia

Elliot Stieglitz, MD, Camille B Troup, PhD, Laura C Gelston, ScM, Eric D Chow, PhD, Kristie B Yu, Jon Akutagawa, BS, Amaro N Taylor-Weiner, BS, Y. Lucy Liu, MD PhD, Peter D Emanuel, MD, Benjamin S Braun, MD PhD, Robert B. Gerbing, MA, Todd A. Alonzo, PhD, Mignon L. Loh, MD

Blood (2014) 124 (21): 410.

https://doi.org/10.1182/blood.V124.21.410.410

Published: 2014

Journal Articles

Hallway gossip between Ras and PI3K pathways

Peter D. Emanuel

Blood (2014) 123 (18): 2751–2753.

https://doi.org/10.1182/blood-2014-03-559039

Published: 2014

Journal Articles

Mutations in GATA2 are rare in juvenile myelomonocytic leukemia

Elliot Stieglitz, Y. Lucy Liu, Peter D. Emanuel, Robert P. Castleberry, Todd M. Cooper, Kevin M. Shannon, Mignon L. Loh

Blood (2014) 123 (9): 1426–1427.

https://doi.org/10.1182/blood-2013-11-531079

Published: 2014

Journal Articles

Mutations In GATA2 Are Rare In Juvenile Myelomonocytic Leukemia

Elliot Stieglitz, MD, Y. Lucy Liu, MD, PhD, Peter D. Emanuel, MD, Robert P. Castleberry, MD, Todd Michael Cooper, Kevin Shannon, MD, Mignon L. Loh, MD

Blood (2013) 122 (21): 1526.

https://doi.org/10.1182/blood.V122.21.1526.1526

Published: 2013

Journal Articles

Overexpression Of DNMT3a and DNMT3b Is Related To Downregulation Of Mir-29a In Juvenile Myelomonocytic Leukemia (JMML)

Y. Lucy Liu, MD, PhD, Shelly Y. Lensing, MS, Yan Yan, MD, Cody Webster, BS, Peter D. Emanuel, MD

Blood (2013) 122 (21): 4890.

https://doi.org/10.1182/blood.V122.21.4890.4890

Published: 2013

Journal Articles

Mir-183 Over-Expression: A Potential Biomarker for Juvenile Myelomonocytic Leukemia (JMML).

Y. Lucy Liu, MD, PhD, Yan Yan, MD, Shelly Y. Lensing, MS, Todd Cooper, DO, Peter D. Emanuel, MD

Blood (2012) 120 (21): 2558.

https://doi.org/10.1182/blood.V120.21.2558.2558

Published: 2012

Journal Articles

A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial

Jerald P. Radich, MD, Kenneth J. Kopecky, PhD, Suzanne Kamel-Reid, PhD, Wendy Stock, MD, Elisabeth Paietta, PhD, Martha Wadleigh, MD, Richard A. Larson, MD, Peter D. Emanuel, MD, Martin S. Tallman, MD, Jeffrey Lipton, MD, FRCPC, Stephen Couban, BSc, MD, Michael W. Deininger, MD, PhD, Frederick R. Appelbaum, MD, Brian J. Druker, MD

Blood (2010) 116 (21): LBA-6.

https://doi.org/10.1182/blood.V116.21.LBA-6.LBA-6

Published: 2010

Journal Articles

Mutations in CBL occur frequently in juvenile myelomonocytic leukemia

Blood (2009) 114 (9): 1859–1863.

https://doi.org/10.1182/blood-2009-01-198416

Published: 2009

Includes: Supplemental data

Journal Articles

Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia

Sophie Archambeault, Nikki J. Flores, Ayami Yoshimi, Christian P. Kratz, Miriam Reising, Alexandra Fischer, Peter Noellke, Franco Locatelli, Petr Sedlacek, Christian Flotho, Marco Zecca, Peter D. Emanuel, Robert P. Castleberry, Charlotte M. Niemeyer, Peter Bader, Mignon L. Loh

Blood (2008) 111 (3): 1124–1127.

https://doi.org/10.1182/blood-2007-06-093302

Published: 2008

Includes: Supplemental data

Journal Articles

Drifting precariously due to lost tyrosines

Peter D. Emanuel

Blood (2007) 109 (1): 7–8.

https://doi.org/10.1182/blood-2006-10-051185

Published: 2007

Journal Articles

Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies

Karen Stephens, Molly Weaver, Kathleen A. Leppig, Kyoko Maruyama, Peter D. Emanuel, Michelle M. Le Beau, Kevin M. Shannon

Blood (2006) 108 (5): 1684–1689.

https://doi.org/10.1182/blood-2005-11-011486

Published: 2006

Includes: Supplemental data

Journal Articles

Phase II Window Study of the Farnesyltransferase Inhibitor R115777 (Zarnestra®) in Untreated Juvenile Myelomonocytic Leukemia (JMML): A Children’s Oncology Group Study.

Robert P. Castleberry, MD, Mignon L. Loh, MD, Nalini Jayaprakash, April Peterson, Vicky Casey, Myron Chang, PhD, Brigitte Widemann, MD, Peter D. Emanuel, MD

Blood (2005) 106 (11): 2587.

https://doi.org/10.1182/blood.V106.11.2587.2587

Published: 2005

Journal Articles

The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease

Christian P. Kratz, Charlotte M. Niemeyer, Robert P. Castleberry, Mualla Cetin, Eva Bergsträsser, Peter D. Emanuel, Henrik Hasle, Gabriela Kardos, Cornelia Klein, Seiji Kojima, Jan Stary, Monika Trebo, Marco Zecca, Bruce D. Gelb, Marco Tartaglia, Mignon L. Loh

Blood (2005) 106 (6): 2183–2185.

https://doi.org/10.1182/blood-2005-02-0531

Published: 2005

Journal Articles

Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis

Mignon L. Loh, Shashaank Vattikuti, Suzanne Schubbert, Melissa G. Reynolds, Elaine Carlson, Kenneth H. Lieuw, Jennifer W. Cheng, Connie M. Lee, David Stokoe, Jeannette M. Bonifas, Nicole P. Curtiss, Jason Gotlib, Soheil Meshinchi, Michelle M. Le Beau, Peter D. Emanuel, Kevin M. Shannon

Blood (2004) 103 (6): 2325–2331.

https://doi.org/10.1182/blood-2003-09-3287

Published: 2004

Journal Articles

Purification and characterization of the yeast-expressed erythropoietin mutant Epo (R103A), a specific inhibitor of human primary hematopoietic cell erythropoiesis

Suzanne Burns, Murat O. Arcasoy, Li Li, Elizabeth Kurian, Katri Selander, Peter D. Emanuel, Kevin W. Harris

Blood (2002) 99 (12): 4400–4405.

https://doi.org/10.1182/blood.V99.12.4400

Published: 2002

NARROW

MLN0128, a Potential Target Therapy for Myeloid Proliferation Neoplasia (MPN) with a Benefit of Prolonging Survival

Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy

Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia

Opposite Effects of M1 and M2 Macrophages on Hematopoietic Stem Cell Self-Renewal and Ex Vivo Expansion

Timing of the Loss of Pten Is Critical in Determining the Disease Phenotype in Mice- a Mouse Model for Pediatric Mixed MDS/MPN

Subclonal Mutations in SETBP1 Predict Relapse in Juvenile Myelomonocytic Leukemia

Hallway gossip between Ras and PI3K pathways

Mutations in GATA2 are rare in juvenile myelomonocytic leukemia

Mutations In GATA2 Are Rare In Juvenile Myelomonocytic Leukemia

Overexpression Of DNMT3a and DNMT3b Is Related To Downregulation Of Mir-29a In Juvenile Myelomonocytic Leukemia (JMML)

Mir-183 Over-Expression: A Potential Biomarker for Juvenile Myelomonocytic Leukemia (JMML).

A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial

Mutations in CBL occur frequently in juvenile myelomonocytic leukemia

Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia

Drifting precariously due to lost tyrosines

Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies

Phase II Window Study of the Farnesyltransferase Inhibitor R115777 (Zarnestra®) in Untreated Juvenile Myelomonocytic Leukemia (JMML): A Children’s Oncology Group Study.

The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease

Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis

Purification and characterization of the yeast-expressed erythropoietin mutant Epo (R103A), a specific inhibitor of human primary hematopoietic cell erythropoiesis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only